ArticleScientific reports2026
Breast tumor microbiome regulates anti-tumor immunity and T cell-associated metabolites.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.Gut microbes · 2026Review
- Tumor-infiltrating microbes and therapy response: a new frontier in triple-negative breast cancer precision oncology.Journal for immunotherapy of cancer · 2026Article
- The role of the intratumoral microbiota in breast cancer metastasis and immune regulation: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Intratumoral Microbiota Correlates with AP-2 Expression: A Pan-Cancer Map with Cohort-Specific Prognostic and Molecular Footprints.International journal of molecular sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
The breast tumor microbiome has emerged as a potential regulator of tumor immunity, yet its interactions with intratumoral lymphocytes and metabolites remain poorly defined. Here, we investigated relationships among CD8+ tumor-infiltrating lymphocytes (TILs), the breast tumor microbiome, and tumor metabolome. In a cohort of 46 breast cancer patients, Staphylococcus was the only bacterial genus whose intratumoral abundance positively correlated with cytotoxic CD8+ T cell markers and innate-like T cell signatures, including multiple KLR-family receptors. Several metabolites were significantly associated with CD8+ TILs, among which NADH, γ-glutamyltryptophan, and γ-glutamylglutamate differed between Staphylococcus-positive and Staphylococcus-negative tumors. Analysis of an independent cohort of 314 treatment-naïve patients further showed that the association between intratumoral Staphylococcus, heightened CD8+ T cell activity, and the KLR-associated innate-like T cell program was specific to triple-negative breast cancer (TNBC). In TNBC mouse models, direct intratumoral injection of Staphylococcus aureus depleted intratumoral NAD metabolites and suppressed tumor growth by activating CD8+ TILs. Together, these findings identify a link between low-biomass intratumoral bacteria and local anti-tumor immunity, and highlight Staphylococcus and TIL-associated metabolites as potential biomarkers and therapeutic targets for breast cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.